During GLP-1 treatment , maintain regular contact with your healthcare team and report: Any new or worsening anxiety symptoms , including excessive worry, panic attacks, or physical anxiety symptoms Changes in mood , sleep patterns, or appetite beyond expected treatment effects Difficulty coping with side effects such as nausea, which may exacerbate anxiety Concerns about body image or eating behaviours as weight changes occur NICE guidance recommends holistic care for people with diabetes and obesity, recognising the importance of psychological wellbeing
But retatrutide, a triple-receptor agonist targeting GLP-1, GIP, and glucagon simultaneously, delivered weight loss numbers in Phase 3 trials that made researchers rethink what pharmaceutical intervention could achieve
Obesity and kidney disease: hidden consequences of the epidemic
The second is single molecules engaging four receptors, with early-stage preclinical literature describing addition of amylin receptor activity to GLP-1, GIP, and glucagon coverage [4].
Moderate alcohol consumption (if any) is recommended, and you should discuss your specific situation with your healthcare provider
